Steroid News and Research

RSS

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Harbor BioSciences to raise $2.06M through sale of common stock shares and warrants

Harbor BioSciences, Inc. announced today that it has entered into an agreement with certain institutional investors to raise approximately $2.06 million in gross proceeds through the sale of approximately 5.9 million shares of its common stock and warrants to purchase approximately 3.5 million shares of its common stock.

7 Jun 2010

CPAP treatment may be a better option for preterm infants

A national study involving a UT Southwestern Medical Center neonatologist provides new insight into how much oxygen preterm infants should receive as well as the optimal way to deliver it to them.

3 Jun 2010

NSF International tests, certifies nutritional supplements to prevent unacceptable contaminants

Recent news coverage has consumers concerned about the alarming amount of contaminants, such as pesticides and heavy metals, being found in herbal supplements. NSF International, an independent, not-for-profit public health organization, helps ease these concerns by testing and certifying supplements to ensure they are free of undeclared substances and unacceptable contaminants.

29 May 2010

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

27 May 2010

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.

21 May 2010

Zebrafish may help scientists reveal function of mysterious enzyme linked to steroid cortisol

Michael E. Baker, PhD, a researcher at the University of California, San Diego School of Medicine has discovered that zebrafish - an important animal model in disease and environmental studies - could provide the means to help scientists eventually reveal the function of a mysterious enzyme linked to the steroid cortisol, and found in the human brain.

20 May 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

19 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

Vidazorb Belly Boost probiotic supplement relieves children from eczema

May is National Asthma and Allergy Awareness Month and, though many parents deal with their kids' allergies year-round, it's a time for education on the subject. One allergic reaction to food, fabric, grass, pollen, environmental factors, etc. is eczema, which recent statistics show develops in one out of ten children before the age of five.

18 May 2010

University of Leeds researchers identify natural defence mechanism against heart disease

A natural defence mechanism against heart disease could be switched on by steroids sold as health supplements, according to researchers at the University of Leeds.

18 May 2010

FDA issues complete response letter for roflumilast NDA

Forest Laboratories, Inc. and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

18 May 2010

Early CPAP as effective for preemies as ventilator, with fewer complications: Study

Two findings from an NIH research network study provide new information on how much oxygen very preterm infants should receive starting on the first day of life and the most effective means to deliver it to them.

17 May 2010

Female sex hormones may work with estrogen in reducing airway constriction: Research

Female sex hormones may work with beta-agonists in reducing airway constriction, according to new bench research from the Mayo Clinic.

17 May 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.

13 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Steroids can raise cardiovascular risks in post-transplant patients

Post-transplant patients who have been removed from a corticosteroid regimen have fewer cardiovascular events than those patients on steroids, increasing their graft survival rates and reducing early mortality, according to study results being presented this week by University of Cincinnati (UC) transplantation researchers.

10 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

Steroid News and Research

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Harbor BioSciences to raise $2.06M through sale of common stock shares and warrants

CPAP treatment may be a better option for preterm infants

NSF International tests, certifies nutritional supplements to prevent unacceptable contaminants

Pfizer plans recruitment halt to EMPHASIS-HF trial

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Zebrafish may help scientists reveal function of mysterious enzyme linked to steroid cortisol

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Vidazorb Belly Boost probiotic supplement relieves children from eczema

University of Leeds researchers identify natural defence mechanism against heart disease

FDA issues complete response letter for roflumilast NDA

Early CPAP as effective for preemies as ventilator, with fewer complications: Study

Female sex hormones may work with estrogen in reducing airway constriction: Research

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Steroids can raise cardiovascular risks in post-transplant patients

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News